Multiply transfused patients of severe aplastic anemia are at increased risk of graft rejection. Five such patients underwent peripheral blood stem cell transplantation from HLA-identical siblings with a fludarabine-based protocol. The conditioning consisted of fludarabine 30 mg/m 2 / day Â 6 days, cyclophosphamide 60 mg/kg/day Â 2 days and horse antithymocyte globulin (ATG) Â 4 days. Two different ATG preparations were used: ATGAM (dose 30 mg/kg/day Â 4 days) or Thymogam (dose 40 mg/kg/ day Â 4 days). Engraftment: median time to absolute neutrophil count (ANC) 40.5 Â 10 9 /l was 11 days (range: 8-17) and median time to platelet count 420 Â 10 9 /l was 11 days (range: 9-17). At a median follow-up of 171 days (range: 47-389), there has been no graft rejection and all patients are in complete remission. Acute GVHD (grade 1) occurred in one patient only. Chronic GVHD developed in two patients (extensive in one and limited in another). The transplants were performed in non-HEPA filter rooms. In only one patient, systemic antifungal therapy (voriconazole) was used. The use of Thymogam brand of ATG for conditioning is being reported for the first time. Our experience suggests that this fludarabine-based protocol allows rapid sustained engraftment in high-risk patients without significant immediate toxicity.
Introduction
Bone marrow transplantation (BMT) is a curative therapy for aplastic anemia, but the incidence of graft rejection in older literature is reported as between 30 and 60%. 1 With improvement in transplant practices, the graft failure rates have fallen to about 10%. 2 In developing countries, most patients are multiply transfused before transplant. Owing to economic reasons, leukocyte filters are rarely used and occasionally blood from family donors is transfused because of blood shortage. Therefore, the risk of rejection is much higher. Even with current conditioning protocols and immunosuppression, the graft failure rates in HLAidentical sibling transplants have been reported as 31% from India. 3 We present our experience of a fludarabine, cyclophosphamide and antithymocyte globulin (ATG) conditioning regimen for hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings.
There is no standard ATG preparation recommended for HSCT. Some studies have preferred rabbit ATG over horse ATG 4, 5 for conditioning in aplastic anemia. We have used horse ATG in our patients, from two different sourcesPfizer (USA) and Bharat Serums and Vaccines (India). The Indian preparation has been used for HSCT for the first time.
Patients and methods

Patient and donor selection
From November 2004 to October 2005, five patients with severe aplastic anemia underwent allogeneic peripheral blood stem cell transplant from six-antigen HLA-matched sibling donors at our center. All had undergone a bone marrow aspirate and biopsy to confirm bone marrow aplasia, and peripheral blood counts showed pancytopenia consistent with severe aplastic anemia. Fanconi's anemia was excluded by stress cytogenetics using mitomycin C. Donors were selected based on HLA molecular typing for class I and II antigens.
Conditioning regimen and stem cell source All patients received the same conditioning regimen. This comprised of fludarabine 30 mg/m 2 /day (days À10 to À5), cyclophosphamide 60 mg/kg/day for 2 days (day À6 and À5) along with hydration and intravenous mesna and ATG. Two different ATG preparations were used, based on economic criteria. The first preference was ATG (ATGAM) from Pfizer (Pharmacia & Upjohn Company, Kalamazoo, Michigan 49001, USA) in a dose of 30 mg/kg/ day. If this was not affordable, the alternative was ATG (Thymogam) from Bharat Serums and Vaccines (Mumbai, India) and, on recommendations of the company, a higher dose of 40 mg/kg/day was used. Antithymocyte globulin was administered for 4 days (days À5 to À2).
The stem cell source was G-CSF-mobilized peripheral blood stem cells, which were infused on day 0 of the conditioning regimen. The minimum target cell dose was 3 Â 10 6 cells/kg CD34 þ cells. If the dose collected was less than 3 Â 10 6 cells/kg, the harvest was repeated the next day to increase the dose and both days were taken as day 0. The CD34 þ cell estimation was made on the final collection of apheresis product, and the report was available within 2 h. The CD34 þ cell estimation was made by flow cytometry using the Milan Mulhouse Protocol 6 using a FACS Calibur (Becton Dickinson). For each estimation, 50 000 cells were studied, with CD34 þ cells expressed as a percent of the total population of leukocytes.
GVHD prophylaxis
Patients received cyclosporine 5 mg/kg/day intravenously in two divided doses from day À1 and the dose was adjusted to keep trough levels between 200 and 300 ng/ml. This was changed to appropriate oral dose by days 10-14, and was continued at full doses for 6 months, then gradually tapered off over 6 months. Methotrexate was given intravenously at a dose of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11.
Supportive care
As HEPA filtered rooms are not available in our center, patients were nursed in non-HEPA filtered air conditioned private rooms with barrier nursing; wet mopping of the room was carried out twice daily, and entry was restricted to two attendants. Cooked food and mineral or boiled water was allowed. Patients received anti-microbial prophylaxis: oral ciprofloxacin, fluconazole and acyclovir as antibacterial, antifungal and antiviral prophylaxis, respectively. Oral Co-trimoxazole was started on day À6, discontinued 1 day before stem cell infusion and restarted after neutrophil recovery. Hemoglobin was maintained above 9 g/dl and platelet counts above 20 Â 10 9 /l by blood and platelet transfusions (irradiated and filtered). G-CSF was started 24 h after stem cell infusion and discontinued when the ANC remained above 0.5 Â 10 9 /l on 2 consecutive days.
Fever was defined as a temperature of more than 1011F, or more than 100.41F for more than 1 h. Any febrile episode was treated with broad-spectrum antibiotics. First line cover consisted of piperacillin-tazobactam (Zosyn), amikacin7teicoplanin (Targocid). Systemic antifungals were added if fever persisted for more than 3 days while on antibiotic cover.
Engraftment
Day of myeloid engraftment was defined as the first of 3 consecutive days with ANC more than 0.5 Â 10 9 /l. Platelet engraftment was defined as unsupported platelet count maintained above 20 Â 10 9 /l.
Results
Patient characteristics
The median age of the patient group was 18 years (range 17-36 years). All the patients were multiply transfused with non-leukocyte-depleted blood products; the median number of transfused packed red cells/platelet concentrates was 30 (range 23-47). Before the transplant, all the patients were on androgens (stanozolol 2 mg/kg/day) and three patients were also receiving cyclosporine 5 mg/kg/day. Patient number 4 had a history of seizure disorder for which she had been receiving carbamazepine, where as patient number 1 had cyanotic heart disease, which had been operated in the first year of life. The median duration of illness before transplant was 8 months (range 1.5-108 months) ( Table 1) .
Patient number 1 was admitted and treated 1 month before transplant for pneumonia and a week before transplant he had fever with a furuncle on the face. Patient number 3 had developed appendicitis 3 months before transplant and was treated conservatively resulting in formation of an appendicular lump. There was recurrence of local pain with fever 1 month before transplant, and cellulitis of face 10 days before the transplant. Patient number 4 had a history of fever and respiratory infection 2 weeks before the transplant.
Cell dose, engraftment and toxicity
The median dose of CD34 þ cells infused was 4.81 Â 10 6 /kg (range 1.9-9.15). In patient 3, the dose of stem cells collected was below the desired target. The median day of myeloid engraftment was 11 days (range 8-17 days) and all patients also attained an ANC of more than 1.0 Â 10 9 /l on the same day. Unsupported platelet count of more than 20 Â 10 9 /l was attained at a median of 11 days (range 9-17 days) and 450 Â 10 9 /l at a median of 13 days (range 9-17 days). Patient number 2 underwent ABO mismatched transplant (donor B þ ; recipient A þ ) and had delayed erythroid engraftment, for which erythropoeitin was administered for 2 months post transplant and the hemoglobin normalized. There was minimal conditioning induced toxicity. All the patients had mild infusion-related fever during infusion of ATG. There was no serum sickness or anaphylaxis. There was no veno-occlusive disease.
Infections
During conditioning, three patients developed fever for which they received broad-spectrum antibiotics (Table 1) . After day 0, all patients had episodes of febrile neutropenia, but focus of infection could be documented only in patient 
GVHD
Patient number 1 had grade 2 acute GVHD (hepatic), which developed on day 38 post transplant. He was treated with oral steroids, which were subsequently tapered. At day 184 post transplant, he developed extensive skin GVHD (biopsy proven) with subsequent eye, oral mucosa and liver involvement. Initially, corticosteroids were added to cyclosporine, but subsequently these were replaced by mycophenolate mofetil from the 10th month post transplant. No other patient has developed acute GVHD. Patient number 3 developed limited chronic GVHD involving the liver on day 114 post transplant, which resolved on adding oral steroids to cyclosporine.
Survival and outcome
At a median follow-up of 171 days (range 47-389), all patients are alive and in complete remission. One patient has extensive chronic GVHD controlled on immunosuppression. No late infections or other complications have occurred. No molecular chimerism studies were performed. In patients number 1, 2 and 5, where there was ABO blood group incompatibility, a change of blood group was documented.
Discussion
The problems of bone marrow transplant in developing countries are similar to those seen two decades earlier in the West. The risk factors for graft failure or poor survival have evolved over time and are identified as a low marrow cell dose, 7, 8 pretransplant blood transfusions (20 or more), pretransplant infections, interval between diagnosis and transplant more than 1 month, 9 and any therapy consisting of immunosuppression or androgens, before the transplant. 10 The outcome in patients with graft failure is poor, especially in those with nonengraftment. 11 In those patients who have initial engraftment but subsequent rejection, about 60% can be salvaged with a second bone marrow transplant. 11 Most patients in developing countries have multiple poor risk factors, and owing to economic and resource constraints, a second transplant is not a feasible option. It is therefore critical to minimize the chances of graft failure in the first transplant.
Increasing intensity of conditioning is one strategy to reduce graft rejection. Addition of radiation to cyclophosphamide has reduced graft failure, but not improved survival owing to higher risk of GVHD, interstitial pneumonia and late complications of radiation. 2, 10 Addition of ATG to cyclophosphamide has led to superior survival 12 and is considered standard therapy for multiply transfused patients. 13, 14 However, the high graft rejections seen in India with these protocols 3 and subsequent poor outcome made us search for more intense conditioning regimens.
Addition of fludarabine to cyclophosphamide and ATG has been recommended for unrelated transplant in severe aplastic anemia 13 and has been reported in limited series for severe aplastic anemia 4, 15 and in Fanconi's anemia. 16 We chose to use this option in related transplants, because of the multiple risk factors for graft failure in our patients.
To reduce chances of graft failure, supplementation with donor buffy coat cells has been used, but this resulted in Table 1 Patient characteristics, engraftment data and follow-up 
Fludarabine for transplant in aplastic anemia R Kumar et al more chronic GVHD. 1,2 The use of G-CSF-mobilized peripheral blood stem cells (PBSC) for transplants results in a larger collection of stem cells, and presumably less graft failure, but with an increased risk of chronic GVHD. 2, 17 The other advantage of PBSC transplant is more rapid neutrophil and platelet engraftment, 18 which would reduce the risk of early infections and cost of supportive therapy. As we do not have facilities of HEPA filter rooms, we hypothesized that early engraftment would minimize the risk of increased infections. We therefore chose to use PBSC as the stem cell source, although we do not know if the potential advantages would be neutralized by chronic GVHD.
Fludarabine-based regimens for HSCT in aplastic anemia have been described, but there has been considerable variation in doses and preparation. 4, 13, 15 Antithymocyte globulin given during conditioning is known to reduce both acute and chronic GVHD, especially if it is given nearer the day of transplant. 19 The circulating ATG produces an in vivo T-cell depletion of the infused donor T cells, as serum levels may be quite high at the time of transplant. As we were using PBSC, we used a high dose of ATG to reduce the chances of chronic GVHD.
We have been using horse ATG (ATGAM) for immunosuppressive therapy for our aplastic anemia patients and preferred to continue with the same preparation. Unfortunately, the preparation is expensive and was unaffordable in two cases, patients 1 and 5. In these patients, economic considerations made us use the Indian preparation, as it less expensive. However, there is no literature on use of this preparation for HSCT. As our preliminary experience with Thymogam as an immunosuppressant in aplastic anemia was encouraging, we decided to use it with patients' informed consent. On advice of the company, we chose a higher dose than with ATGAM. In patient 1, the estimated cost of ATGAM at a dose of 30 mg/kg/day Â 4 days was US $ 6500, where as the cost of Thymogam at a dose of 40 mg/kg/day was US $ 3000 only. Apart from this variation, the protocols were identical. Both neutrophil and platelet engraftments were rapid and sustained in all cases. This is especially significant, as all the patients had multiple risk factors for graft rejection. Acute GVHD did not occur in four patients and was mild in one. Extensive chronic GVHD has occurred in patient 1, where as limited chronic GVHD has occurred in another. With the limited follow-up, it is not possible to draw any conclusions on occurrence and severity of chronic GVHD and any beneficial role of high doses of ATG that we have used.
We were concerned about a higher infection risk, especially of fungal infections, in our patients as we do not have HEPA filter rooms in our center. Recently, the protective value of specialized airway ventilation systems and HEPA filter rooms has been questioned and in some centers even allogeneic transplants have been made successfully without protective isolation. 20, 21 There are no such data from developing countries where environmental pollution is higher, and HEPA filter rooms are considered advisable. 3 Despite a very immunosuppressive conditioning in our high-risk patients, and routine protective isolation, we had no refractory or life-threatening infections.
Systemic antifungal agents were not required in four of our patients. In patient 4, voriconazole was added empirically on development of pneumonia, at an early stage. The possible reasons for the low rate of infective complications are the use of prophylactic ciprofloxacin/ fluconazole and early empirical use of effective antimicrobials. An early neutrophil recovery owing to use of PBSC supplemented by G-CSF is likely to have contributed to the favorable outcome.
This experience shows that in patients of severe aplastic anemia at high risk of graft rejection, a conditioning regimen of fludarabine, cyclophosphamide and ATG resulted in successful engraftment. A longer follow-up will show if use of ATG in conditioning can reduce the incidence and severity of chronic GVHD. In countries with similar patient profiles and shortage of conventional BMT units, such a strategy appears promising.
